EMA’s CHMP Recommends New Use for Novo Nordisk’s Basal Insulin
Novo Nordisk reports that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the expanded use of Levemir (insulin detemir) in children with diabetes as young as one year old.
Levemir (insulin detemir) is a long-acting basal insulin for the treatment of diabetes. Levemir was launched in 2004 and is commercially available in 90 countries.
Source: Novo Nordisk